Overview

Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Prazosin is an alpha-1 adrenergic receptor antagonist that has been used successfully in the treatment of trauma nightmares and sleep disturbance in combat veterans with PTSD, and alcohol dependence. The objective of this study is to evaluate the efficacy of prazosin (16mg) versus placebo in reducing alcohol consumption and decreasing symptoms of PTSD in patients with comorbid AD and PTSD.
Phase:
Phase 3
Details
Lead Sponsor:
Yale University
Treatments:
Ethanol
Prazosin